$NVLX Gets Exclusive Worldwide License To Use Unique Combine Cell-in-a-Box(R) and Cannabinoid-Based Medicine For Treatment Development

Nuvilex Obtains Exclusive Worldwide License to Develop Disease Treatments That Combine Cell-in-a-Box(R)…

$NVLX Announces Newly Formed Diabetes Consortium

Nuvilex Announces the Formation of a Diabetes Consortium for the Development of…

$NVLX Announces Preliminary Data From Preclinical Study is Promising

Nuvilex Announces Preliminary Data From Preclinical Study of Effects of Its Pancreatic…

$NVLX Submits Application in Australia To Get Orphan Drug Designation For Pancreatic Cancer Treatment

Nuvilex Applies in Australia for the Orphan Drug Designation for Pancreatic Cancer…

$NVLX Will Commercialize Breakthrough Diabetes Research

Breakthrough Diabetes Research to Be Commercialized by US-Based Nuvilex, Inc. SYDNEY, AUSTRALIA–(Marketwired…

$NVLX is “Cutting Edge”

Nuvilex, Inc. Engaged in “Cutting Edge” Cannabis Preclinical Studies Using Model Compounds…

$NVLX Cancer Treatment Making Headlines

Nuvilex’s Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive…

$NVLX “It’s My Cell-in-a-Box”

Nuvilex Applies to FDA for Orphan Drug Designation for Its Cell-in-a-Box(R) Treatment…